Xin Lang Cai Jing·2025-12-02 05:58Core Viewpoint - Rongchang Biopharmaceuticals has experienced significant stock price fluctuations and growth in revenue, while also facing challenges in net profit, indicating a mixed financial performance in the biopharmaceutical sector. Group 1: Stock Performance - On December 2, Rongchang Biopharmaceuticals' stock fell by 2.09%, trading at 93.25 CNY per share with a total market capitalization of 52.566 billion CNY [1] - The stock has increased by 209.70% year-to-date, with a 6.57% rise over the last five trading days, but has seen a decline of 3.61% over the last 20 days and 3.69% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on June 26, where it recorded a net buy of -137 million CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Rongchang Biopharmaceuticals reported a revenue of 1.72 billion CNY, reflecting a year-on-year growth of 42.27% [3] - The net profit attributable to shareholders was -551 million CNY, showing a year-on-year increase of 48.60% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased by 18.33% to 15,300, while the average number of circulating shares per person decreased by 15.54% to 10,639 shares [3] - The second-largest shareholder is Hong Kong Central Clearing Limited, holding 8.8418 million shares, a decrease of 510,800 shares from the previous period [4] - New shareholders include Guangfa Medical Care Stock A, which holds 3.9875 million shares [4]